Metraipolis › archive › dc_0d8a1519fa42

Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic… — Europe PMC PMID:41844573

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41844573
DOI
10.1038/s41408-[numero omesso]-8
License (as archived)
solo-consultazione
Archived
2026-11-04T08:29:26.846Z
SHA-256 of the archived text
b038746ccb0e476c6a99dfad5acbe15aa73ec1eb2a8f38480d812c2ade7762f4
Stable URL of this page
https://metraipolis.com/documento/dc_0d8a1519fa42

How to cite

Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic… — Europe PMC PMID:41844573 — Europe PMC (en), https://europepmc.org/article/MED/41844573 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_0d8a1519fa42 (Metraipolis archive dc_0d8a1519fa42, sha256 b038746ccb0e476c6a99dfad5acbe15aa73ec1eb2a8f38480d812c2ade7762f4)
BibTeX
@misc{dc0d8a1519fa42,
  title = {Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic… — Europe PMC PMID:41844573},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41844573},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_0d8a1519fa42; sha256 b038746ccb0e476c6a99dfad5acbe15aa73ec1eb2a8f38480d812c2ade7762f4},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41844573. Agents can read the archived copy with the MCP tool read_document.